MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.86
-0.29 (-3.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.15
Open9.08
Bid8.40 x 900
Ask39.80 x 800
Day's Range8.83 - 9.31
52 Week Range6.30 - 14.50
Volume82,327
Avg. Volume84,631
Market Cap371.068M
Beta (3Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.41
Earnings DateApr 26, 2017 - May 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Simply Wall St.3 days ago

    Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...

  • GlobeNewswire3 days ago

    MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco

    LA JOLLA, Calif., Dec. 12, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • Zacks Small Cap Researchlast month

    MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy…

    In August 2018, MediciNova, Inc. (MNOV) announced plans to conduct a Phase 2/3 trial of MN-166 in degenerative cervical myelopathy (DCM) through an agreement with the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Principal Investigator is Dr. Mark Kotter and the trial is being funded by a grant from the National Institute for Health Research (NIHR) in the United Kingdom. MediciNova is not funding the trial but will provide the study drug supply, regulatory support, and safety monitoring support.

  • Benzinga2 months ago

    The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...

  • GlobeNewswire2 months ago

    MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma

    LA JOLLA, Calif., Oct. 04, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • Zacks Small Cap Research3 months ago

    MNOV: Positive FDA Feedback on ALS Phase 3 Plan…

    On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.

  • GlobeNewswire3 months ago

    MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug Administration) regarding MediciNova’s Phase 3 clinical development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If a single trial shows that MN-166 (ibudilast) has a statistically significant benefit compared to placebo in a measure of functional activity, such as ALSFRS-R, an additional trial may not be necessary. In order to detect the maximal potential benefit of MN-166 (ibudilast), FDA encouraged including a broad ALS population, with randomization that is stratified by baseline disease severity.

  • GlobeNewswire3 months ago

    MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market.

  • Zacks Small Cap Research5 months ago

    MNOV: Plenty of Cash to Advance Pipeline Forward

    On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.

  • Zacks Small Cap Research5 months ago

    MNOV: Encouraging Data from Subgroup Analysis of ALS Study

    This group was comprised of 31 subjects out of a total of 49 subjects in the full analysis set. A second subgroup comprised of 39 subjects (out of a total of 67 subjects in the full analysis set) who had either bulbar onset or upper limb onset ALS with or without NIV (the “Early ALS + NIV subgroup”). The score is utilized to keep track of the health of all ALS patients, and is a common outcome measure in ALS clinical trials.

  • When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?
    Simply Wall St.6 months ago

    When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?

    MediciNova Inc’s (NASDAQ:MNOV): MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in theRead More...

  • Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately
    Simply Wall St.7 months ago

    Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately

    After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...